Literature DB >> 16197951

Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals.

Haralampos J Milionis1, Theodosios D Filippatos, Tsironis Loukas, Eleni T Bairaktari, Alexandros D Tselepis, Moses S Elisaf.   

Abstract

In a population-based case-control study, we investigated the association of acute ischaemic stroke with lipoprotein(a) (Lp(a)) levels and apolipoprotein (Apo) (a) isoform size in subjects aged older than 70 years. A total of 163 patients with a first-ever-in-a-lifetime acute ischaemic/nonembolic stroke and 166 controls were included. Compared to controls, stroke patients exhibited higher Lp(a) concentrations (median value, 12.2 mg/dl versus 6.4 mg/dl, p < 0.001) and a higher frequency of small Apo(a) isoforms (44.2% versus 29.5%, p < 0.01). Multivariate logistic regression analysis showed a significant association of acute ischaemic stroke with Lp(a) levels [adjusted odds ratio (OR), 1.37, 95% CI (1.12-1.67); p = 0.002], and small Apo(a) isoform size [OR, 1.74 (1.10-3.03); p = 0.04]. Compared to subjects with Lp(a) levels in the lowest quintile, those within the highest quintile had a 3.2-times adjusted risk to suffer an acute ischaemic/nonembolic stroke (1.60-6.62, 95% CI; p < 0.001). Furthermore, analysis of interaction between lipid variables revealed that in the presence of elevated Lp(a) levels the inverse relationship between HDL-cholesterol levels and ischaemic stroke was negated [OR, 1.01 (1.00-1.03); p = 0.015]. Our study suggests that determination of Lp(a) levels and Apo(a) isoform size may be important in identifying elderly individuals at risk of ischaemic stroke independently of other risk factors and concurrent metabolic derangements.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16197951     DOI: 10.1016/j.atherosclerosis.2005.08.036

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Lipoprotein(a) and abdominal aortic aneurysm risk: The Atherosclerosis Risk in Communities study.

Authors:  Yasuhiko Kubota; Aaron R Folsom; Christie M Ballantyne; Weihong Tang
Journal:  Atherosclerosis       Date:  2017-11-26       Impact factor: 5.162

2.  Clinical and genetic features in a family with CADASIL and high lipoprotein (a) values.

Authors:  Maolian Gong; Franz Rueschendorf; Peter Marx; Herbert Schulz; Hans-Georg Kraft; Norbert Huebner; Hans-Christian Koennecke
Journal:  J Neurol       Date:  2010-02-09       Impact factor: 4.849

Review 3.  Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?

Authors:  Aris P Agouridis; Christos V Rizos; Moses S Elisaf; Theodosios D Filippatos
Journal:  Rev Diabet Stud       Date:  2013-08-10

4.  Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  James F Meschia; Cheryl Bushnell; Bernadette Boden-Albala; Lynne T Braun; Dawn M Bravata; Seemant Chaturvedi; Mark A Creager; Robert H Eckel; Mitchell S V Elkind; Myriam Fornage; Larry B Goldstein; Steven M Greenberg; Susanna E Horvath; Costantino Iadecola; Edward C Jauch; Wesley S Moore; John A Wilson
Journal:  Stroke       Date:  2014-10-28       Impact factor: 7.914

Review 5.  Anacetrapib, a New CETP Inhibitor: The New Tool for the Management of Dyslipidemias?

Authors:  Theodosios D Filippatos; Anastazia Kei; Moses S Elisaf
Journal:  Diseases       Date:  2017-09-29

6.  Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis.

Authors:  Pradeep Kumar; Priyanka Swarnkar; Shubham Misra; Manabesh Nath
Journal:  Sci Rep       Date:  2021-08-02       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.